Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opening Session Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Dec
09
Today In Oncology
One in Three Families of Children With ALL Face Financial Hardship During Treatment
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
Non-Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo